Evaxion releases transcript of Q2 2026 business update and financial results call
EVAX•Cash position and runway
Cash was $14 million at quarter-end, and net loss was $3.7 million.
Evaxion reiterated its runway into H2 2027, supported by an ATM facility.
Pipeline update on EVX-05
The company introduced preclinical EVX-05, an off-the-shelf vaccine for glioblastoma developed with Duke.
Target discovery has been completed, and 16 ERV fragments were selected from about 1.5 million.
Q2 2026 business update and financial results
Evaxion discussed its Q2 2026 business update and financial results on Aug. 20, led by CEO Helen Tayton-Martin, CSO/COO Birgitte Rono, and CFO Thomas Schmidt.
Management set an October ESMO presentation for three-year Phase 2 EVX-01 melanoma data, including standalone vaccine and anti-PD-1 combination outcomes.
Earlier EVX-01 readouts cited a 75% overall response rate, 25% complete responses, 92% still in response, and 86% of vaccine targets triggering tumor-specific responses.
